P/E ratio for AIM ImmunoTech (AIM)
P/E ratio as of June 2024 (TTM): -0.9498
According to AIM ImmunoTech 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.94975. At the end of 2022 the company had a P/E ratio of -0.7750.
P/E ratio history for AIM ImmunoTech from 2001 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -0.7750 | -66.3% |
| 2021 | -2.30 | -35.75% |
| 2020 | -3.58 | 3355.59% |
| 2019 | -0.1036 | -87.38% |
| 2018 | -0.8207 | -32% |
| 2017 | -1.21 | -42.28% |
| 2016 | -2.09 | 76.42% |
| 2015 | -1.19 | -56.15% |
| 2014 | -2.70 | 0.1% |
| 2013 | -2.70 | 29.6% |
| 2012 | -2.08 | -16.67% |
| 2011 | -2.50 | -54.08% |
| 2010 | -5.44 | -22.22% |
| 2009 | -7.00 | 211.11% |
| 2008 | -2.25 | -28.95% |
| 2007 | -3.17 | -55.38% |
| 2006 | -7.10 | -18.24% |
| 2005 | -8.68 | 114.72% |
| 2004 | -4.04 | -23.08% |
| 2003 | -5.26 | -43.25% |
| 2002 | -9.26 | -40.32% |
| 2001 | -15.5 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 OPKO Health
OPK | -4.78 | 403.06% | 🇺🇸 USA |
 Onconova Therapeutics ONTX | -0.9953 | 4.80% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.